- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03273296
Effect of Antibiotics on Gut Microbiome and Plasma Metabolome
April 3, 2018 updated by: Finnish Institute for Health and Welfare
In recent years it has been observed that the gut microbiome can produce metabolites into systemic circulation and thus have important health effects even outside the gastrointestinal system.
These metabolites may play a role in the pathogenesis of common public health problems such as diabetes, obesity and cardiovascular disorders.
Modern techniques of mass spectrometry-based metabolomics from peripheral blood and gut metagenome sequencing now enable detailed examination of these processes.
Using samples from the FINRISK 2002 cohort, collected by the National Institute for Health and Welfare, we are currently determining the gut microbiome and plasma metabolome from > 7000 participants with 15 years of follow-up for various health outcomes.
This is one of the largest materials of its kind world-wide.
The design does not, however, allow us to draw causal conclusions on the roles of gut bacteria in the composition of plasma metabolome.
To enable conclusions which go beyond statistical associations, we now propose an extension to the FINRISK 2002 study, where we alter the gut bacteriome with a short course of antibiotics and then examine whether a change in plasma metabolomics profile will follow.
At the same time the trial will give important novel information about the effects of commonly used antibiotics on gut bacteriome and on general health.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
39
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Helsinki, Finland, 00271
- National Institute for Health and Welfare
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 74 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Prior participation in the FINRISK 2002 survey and current residence in Helsinki metropolitan area.
- Age range 40-74 years among men and 50-74 years among women.
Exclusion Criteria:
- Known allergy to any antibiotic
- A course of antibiotic during the past year
- Acute infection
- Any major illness (history of myocardial infarction, stroke, diabetes, liver or kidney disease, cancer, psychiatric disease). Uncomplicated hypertension is allowed. Likewise, statin treatment and women's hormone replacement therapy are allowed.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Amoxicillin
|
Amoxicillin (po) 500 mg x 3 per day for 3 days.
|
ACTIVE_COMPARATOR: Azithromycin
|
Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
|
ACTIVE_COMPARATOR: Vancomycin
|
Vancomycin (po) 125 mg x 4 per day for 3 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microbiome
Time Frame: Baseline: 0 days; repeat assessments 2 days and 28 days after end of antibiotics.
|
Change in gut microbiome from baseline to repeat assessments.
|
Baseline: 0 days; repeat assessments 2 days and 28 days after end of antibiotics.
|
Metabolome
Time Frame: Baseline: 0 days; repeat assessments 2 days and 28 days after end of antibiotics.
|
Change in circulating metabolome from baseline to repeat assessments.
|
Baseline: 0 days; repeat assessments 2 days and 28 days after end of antibiotics.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Markus Perola, MD, PhD, Finnish Institute for Health and Welfare
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 15, 2017
Primary Completion (ACTUAL)
December 15, 2017
Study Completion (ACTUAL)
December 15, 2017
Study Registration Dates
First Submitted
September 4, 2017
First Submitted That Met QC Criteria
September 4, 2017
First Posted (ACTUAL)
September 6, 2017
Study Record Updates
Last Update Posted (ACTUAL)
April 4, 2018
Last Update Submitted That Met QC Criteria
April 3, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1341/6.00.00/2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Microbial Colonization
-
Karolinska InstitutetCompletedMicrobial Colonization and Colorectal Disease
-
NHS FifeUniversity of TurkuUnknownDental Caries | Oral Microbial ColonizationUnited Kingdom
-
University Magna GraeciaRecruiting
-
Medical University InnsbruckCompleted
-
BLIS Technologies LimitedRecruiting
-
Min-Tze LIONGInternational Islamic University MalaysiaRecruiting
-
VU University of AmsterdamWageningen University and Research; Maag Lever Darm Stichting; Cidrani; WholeFiber and other collaboratorsActive, not recruiting
-
BLIS Technologies LimitedActive, not recruiting
-
Becton, Dickinson and CompanyCompleted
-
Washington University School of MedicineCompletedMicrobial ColonizationUnited States
Clinical Trials on Amoxicillin
-
Universita degli Studi di GenovaNot yet recruiting
-
Saskatchewan Health Authority - Regina AreaNot yet recruiting
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedPostpartum Sepsis | Postpartum Endometritis | Postpartum FeverCameroon
-
University Medical Centre LjubljanaUniversity of Ljubljana School of Medicine, SloveniaRecruiting
-
Malmö UniversityCompletedAntibiotic Prophylaxis | Infection ControlSweden
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityCompletedHelicobacter Pylori Eradication RateChina
-
Assistance Publique - Hôpitaux de ParisCompletedChronic Obstructive Lung Disease (COLD)France
-
Ranbaxy Laboratories LimitedCompletedHealthyUnited States
-
University Hospital, Clermont-FerrandUnknown
-
Klara Posfay-BarbeGertrude Von Meissner Foundation; Recherche et Développement des HUG; Société...UnknownGroup A Streptococcal PharyngitisSwitzerland